Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab

2019

Blood , Volume 133 - Issue 5 p. 494- 497

Additional Metadata
Persistent URL	doi.org/10.1182/blood-2018-03-839688, hdl.handle.net/1765/115022
Journal	Blood
Organisation	Department of Immunology
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Langerak, A., Ritgen, M., Goede, V., Robrecht, S., Bahlo, J., Fischer, K, … van Dongen, JJM. (2019). Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab. Blood, 133(5), 494–497. doi:10.1182/blood-2018-03-839688

Publication